



Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review

Hyun Uk Chung¹, Jun Hyuk Son²

¹Yeungnam Eye Center, Yeungnam University Hospital, Daegu, Korea

²Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Korea

Lymphoma is the most common primary tumor of the orbit, accounting for 55% of all orbital malignancies. When divided into histopathological subtypes, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) comprises the largest proportion. Clinical manifestations are unspecific, but in patients with slow-growing painless orbital mass, or red conjunctival lesion suggestive of 'salmon patch', ocular adnexa lymphoma (OAL) should be suspected. Although the pathogenetic mechanism of ocular adnexal MALT lymphoma (OAML) is not yet fully understood, the relationship between OAML and *Chlamydia psittaci* has been hypothesized recently, similar to that between gastric MALT lymphoma and *Helicobacter pylori*. This suggests a new treatment option for OAML; bacterial eradication therapy with systemic antibiotics. Several other treatment methods for OAML have been introduced, but no treatment guidelines have been established yet. In this article, we summarize the current knowledge on the clinical features, pathogenesis, diagnostic methods, therapeutic strategies, and prognosis of OAML.

Keywords: *Chlamydia psittaci*; Etiology; Marginal zone B-cell lymphoma; Ocular adnexal lymphoma; Orbital neoplasms

Introduction

Lymphoma is a type of blood malignancy that begins in lymphocytes which include B-lymphocytes, T-lymphocytes, and natural killer (NK) cells. There are two main categories of lymphoma: those presenting with a specific type of cellular abnormality dubbed a Reed-Sternberg cell, called classic Hodgkin lymphomas (HLs), and the others called non-Hodgkin lymphomas (NHLs) [1]. HL accounts for approximately 10% of all lymphomas, while the remaining 90% are NHL [2]. NHL is also divided into B-cell and T-cell lymphomas. B-cell lymphoma accounts for more than 85% of all lymphoid neoplasms [1]. Although orbital lymphoma is rare, accounting for only 1% of all NHL cases, it is the most common primary orbital cancer in adults, accounting for 55% of all ma-

lignancies in the orbit [3-5]. The majority of NHL of the orbit and ocular adnexa are extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) [6]. This review article summarizes the previously published literature on ocular adnexal MALT lymphoma (OAML), with an overview of its clinical features, treatment options, and prognostic outcome.

Clinical features

Ocular adnexal lymphoma (OAL), which mainly involves the conjunctiva, lacrimal gland, orbital fat, lacrimal sac, and eyelid, has various clinical presentations depending on the lesion. In addition, it cannot be easily differentiated from other orbital diseases because it has no pathognomonic signs or symptoms.

Received: June 21, 2021 • Revised: August 1, 2021 • Accepted: August 12, 2021

Corresponding author: Jun Hyuk Son, MD, PhD

Department of Ophthalmology, Yeungnam University College of Medicine, 170 Hyeonchung-ro, Nam-gu, Daegu 42415, Korea

Tel: +82-53-620-3442 • Fax: +82-53-626-5936 • E-mail: sonjh@ynu.ac.kr

Copyright © 2022 Yeungnam University College of Medicine, Yeungnam University Institute of Medical Science

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Conjunctival involvement is observed in 26% of OALs, which shows a characteristic red, swollen, painless lesion called 'salmon patch,' making it easier to detect the disease [7]. However, a high index of suspicion is required because it may mimic chronic conjunctivitis in rare cases [8].

Intraorbital lymphoma usually presents with a variety of symptoms, including proptosis, palpable mass, swelling, ptosis, limited eye motility, displacement of the eye, and diplopia [7,9-12]. In particular, computed tomography (CT) or magnetic resonance imaging (MRI) should be considered in patients with proptosis, especially unilateral proptosis, since it is the most common symptom of orbital B-cell lymphoma [11,13].

Pathogenesis

The histopathological features of OAML are similar to those of other MALT lymphomas. Under physiological conditions, the connective tissues of the orbit are devoid of lymphoid tissue and lymphatic drainage [14]. Hence, for lymphoma to develop in the orbit, organized lymphoid tissue must be acquired first, as observed in gastric MALT lymphoma [15]. Several conditions, including chronic inflammation and autoimmune disorders, are associated with the pathogenesis of OAML.

1. Chronic antigenic stimulation

Over the last few years, the relationship between lymphoma and chronic antigenic stimulation has garnered increasing attention. As a paradigmatic example, *Helicobacter pylori* infection triggers chronic antigenic stimulation and plays a key role in the development of gastric MALT lymphoma [15]. Likewise, the detection of *Chlamydia psittaci* DNA in 80% of patients with OAML suggests that *C. psittaci* infection is related to the development of OAML [16]. *C. psittaci* is the known causative bacterium of psittacosis, which is caused by contact with infected animals, and half of the OAL patients have reported close contact with household animals [16,17]. Potential pathogenesis of OAML related to chlamydial infection is similar to that of gastric MALT lymphoma caused by *H. pylori*. This pathogenesis model is also observed in cutaneous B-cell lymphoma caused by *Borrelia burgdorferi* and small intestinal MALT lymphoma caused by *Campylobacter jejuni*. The chronic inflammation induced by *C. psittaci* facilitates the development of MALT in the orbit. Then, clonal expansion and proliferation of B-cell in the marginal zone of lymphoid follicles could occur in a state of persistent chlamydial infection. These clonal B-cells (antigen-dependent lymphoma clones) invade the germinal center of lymphoid follicles, causing chromosomal aberrations, resulting in an environment in which clonal expansion can continue without

antigenic stimulation (antigen-independent lymphoma clones) [18]. Several studies have confirmed an association between *C. psittaci* and OAL, while others did not, which indicates the possibility of geographical variation [7,13,19-26]. Interestingly, tumor regression was observed in 38% of *C. psittaci* DNA-negative OAL after bacterial eradication therapy with doxycycline, suggesting that other microbial agents, such as doxycycline-sensitive bacteria, may be involved in the development of OAL [27]. Epstein-Barr virus (EBV), human T-cell leukemia virus type 1 (HTLV-1), hepatitis C virus (HCV), and human herpes simplex virus-8 are known to be associated with malignant lymphoma, and one study reported HCV seropositivity in 13% of OAL patients [28,29].

2. Immune disorders

Lymphoma is the most common cancer and the most common cause of cancer-deaths in human immunodeficiency virus (HIV)-infected patients [30,31]. Although the mechanism of lymphoma development in HIV patients is not clearly known, one study found that virologic suppression with highly active antiretroviral therapy reduces the risk of lymphoma [31]. Hence, advanced immunosuppression, higher levels of circulating viremia, and a high prevalence of oncogenic viruses (especially EBV) may be associated with an increased risk of lymphoma in HIV patients [31-34].

In addition, it has been reported that there is an increased risk of NHL in patients with autoimmune disorders such as Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis, Hashimoto thyroiditis, immune thrombocytopenic purpura, and autoimmune hemolytic anemia [35,36].

3. Genetic abnormality

Similar to other malignancies, several chromosomal abnormalities are observed in the OAL. In the case of MALT lymphoma, different chromosomal alterations are detected depending on the site of origin [20]. In particular, trisomy 3 and 18, 5q (ODZ2) and 9p (JMJD2C), t(11;18)(q21;q21), t(14;18)(q32;q21), t(3;14)(p14.1;q32), and A20 inactivation (6q23 deletion) are associated with OAML [20,37]. One study reported a higher incidence of trisomy 3 in orbital MALT lymphoma than in conjunctival MALT lymphoma, while another reported that trisomy 18 was more common in young women with conjunctival involvement, which shows a high recurrence rate [38,39]. However, there is not much data yet on the genetic aspect of OAL, so further investigation is needed to fully understand it.

Diagnosis

The definitive diagnostic method of OAL is histopathologic verifi-

cation. However, neuroimaging techniques, including CT or MRI, are also necessary to measure the size of the lesion or to differentiate it from other orbital diseases. In a two-phase contrast enhancement CT scan, orbital lymphoma shows a decrease in density in the delayed phase, which is in contrast to the orbital inflammatory pseudotumor showing increased density on delayed imaging [40]. An MRI scan shows a mass with isointensity on the T1 image and an iso-hyperintense signal on T2. Furthermore, quantified tumor blood flow (TBF) values measured by arterial spin labeling and apparent diffusion coefficient (ADC) on diffusion-weighted imaging could be helpful in differentiating lymphoma from other expansive orbital diseases. In particular, lymphoma represents high TBF and low ADC values compared to idiopathic orbital inflammatory pseudotumors, which may be difficult to differentiate clinically [41,42]. After determining the size and location of the lesion, a histopathological examination should be performed through an open biopsy [1]. Histopathologic examination of OAML may not always be conclusive since it mainly consists of small lymphoma cells that lack cellular atypia, and have a similar appearance to small lymphocytes [43,44]. Thus, it is often challenging to differentiate lymphoma from reactive lymphoid hyperplasia [44]. In this case, determining the clonal B-cell population by polymerase chain reaction (PCR) analysis of immunoglobulin heavy chain gene rearrangement can help in the differential diagnosis [45]. Further immunohistochemical examination shows CD20+, CD79a+, IgM+ with light-chain restriction, PAX5+, bcl-2+, TCL1+, CD11c+/-, CD43+/-, CD21+/-, CD35+/-, IgD-, CD3-, CD5-, CD10-, CD23-, cyclin D1-, bcl-6-, and MUM1- cells as classical immunophenotype [38,46-51]. In addition, systemic evaluation, such as full-body positron emission tomography-CT and bone marrow biopsy should also be performed [52,53].

Staging

The Ann Arbor staging system, commonly used in the staging of NHL, is a system for the staging of HL [54-56]. This staging system divides the disease into four stages: (I) single localized disease, (II) two or more lesions on one side of the diaphragm, or (III) both sides of the diaphragm, and (IV) metastatic disease. The involvement of the localized extranodal site is recognized by the subscript E (i.e., stage I_E) [57]. However, the Ann Arbor system is not suitable for the staging of OAML because it does not consider anatomic location, multicentricity, bilaterality, or extent of primary tumor infiltration; thus, two-thirds of OAML cases are classified as stage I_E [56,58,59]. To overcome this limitation of the Ann Arbor system, the American Joint Committee on Cancer proposed a new staging system for OAL [60]. This TNM staging system deter-

mines the stage of OAL based on the size and extent of the primary tumor (T), involvement of local lymph nodes (N), and the presence or absence of tumor metastasis (M) [56,59]. Although several studies have demonstrated the usefulness of TNM staging for OAL, new treatment protocols based on this staging system remain to be investigated [58,59].

Treatment

Although many treatment options for OAL have been reported, no definite guidelines have yet been universally accepted. When a therapeutic decision for OAL is made, the location and extension of the tumor, the presence or absence of metastasis, prognostic factors of the patients, and treatment-related toxicity or adverse effects should be considered.

1. Surgical resection

Surgical resection is listed first, not only because it is the most conventional treatment option for tumors but also because it is necessary for the diagnosis of OAL. Some MALT lymphomas of the conjunctiva or lacrimal glands can be completely resected; however, excessive efforts to completely resect lymphoma are not recommended, as they could be associated with a high risk of complications. Furthermore, a study reported that complete resection of OAML did not affect overall survival rates [61]. Surgery can be used in combination with other treatment options, such as chemotherapy and radiation therapy, to reduce the tumor size. For localized low-grade MALT lymphoma in older patients who do not want invasive treatment, the watch-and-wait strategy could be an option after surgical resection or biopsy [61,62].

2. Radiation therapy

Radiation therapy is frequently used in the treatment of OAL and has been the mainstay of treatment for many years. It may be used to eradicate tumors and is also used to reduce the size of the tumor before surgery or as a combination therapy with chemotherapy or immunotherapy. Although there is no gold standard for the dose of radiation, 28–36 Gy is commonly prescribed for low-grade lymphomas such as MALT lymphoma or follicular lymphoma, and 30–40 Gy for high-grade lymphomas such as diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) [62]. In low-grade lymphoma, the 5-year local control rate was 86% for < 30 Gy and 100% for ≥ 30 Gy. In the case of MALT lymphoma alone, the overall local control rate was 96% at 5 years and 86% at 10 years (range, 23.1–45 Gy; median D1.8, 31.8 Gy) [63]. As noted in many studies, radiation therapy shows a good local control rate, but it can cause some adverse effects, including cutaneous re-

actions, cataracts, dry eyes, macular degeneration, retinopathy, and corneal ulceration, particularly at doses of 30 Gy or higher [64-67]. Therefore, some authors prefer ultra-low-dose radiation therapy, which uses only 4–8 Gy in total, and the minimal incidence of adverse effects has been reported [68,69]. However, this remains controversial, as some authors reported a high recurrence rate in low-dose treatment, especially below 30 Gy [12,24,63]. Likewise, a lens shielding technique using a lead contact lens or cylindrical shield to prevent the development of cataract is worth considering, although there are some reports of high recurrence rates [11,12,50,64,65].

3. Chemotherapy

Chemotherapy is often used in OAL with systemic involvement or high-grade lymphomas such as DLBCL. The combination regimen of cyclophosphamide, doxorubicin (hydroxydaunorubicin/adriamycin), vincristine (Oncovin; Eli Lilly and Company, Indianapolis, IN, USA), and prednisone (CHOP) is the most commonly used. Other common combination regimens include hyper-CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine) and CVP (cyclophosphamide, vincristine, and prednisone). As a monotherapy, chlorambucil is frequently used for treating indolent lymphomas, showing a 79% complete response and 21% partial response (PR) rate with good tolerability in orbital MALT lymphoma [70]. Oxaliplatin and purine analogs, including fludarabine and cladribine, have also been used recently [50,71-73].

4. Systemic antibiotics

More than 90% of gastric MALT lymphomas are related to *H. pylori* infection, and after this was proven, bacterial eradication therapy with systemic antibiotics became an important part of treatment [74-76]. A similar relationship between *C. psittaci* and OAL has been proposed. Several authors have reported high rates of *C. psittaci* infection in patients with OAML, 80% in Italy [16] and 78% in South Korea [77]. However, no such association has been found in Japan [21,78], the Netherlands [22], France [79], Cuba [80], and the United States [7,23,38,81], suggesting geographical variation. A multicenter prospective phase II trial conducted in four countries (Chile, Italy, Spain, and Switzerland) showed a good response rate to first-line eradication therapy with doxycycline for OAML; complete remission (CR) in 18%, PR in 47%, and overall response rate (ORR) of 65% [26]. In South Korea, a study on 90 patients with OAML found a 34% ORR with first-line doxycycline treatment. In addition, this study reported that the ORR of second-line treatment with radiotherapy for patients who progressed after doxycycline treatment was 100% [82]. Furthermore, consid-

ering that doxycycline treatment was effective even in 38% of *C. psittaci* DNA-negative patients according to one study, it seems that it could be used in most OAML patients [27]. On the other hand, one author reported that doxycycline treatment in patients who had not been tested for chlamydia infection showed no effect on OAML [83]. In summary, the effectiveness of bacterial eradication therapy with doxycycline for OAML remains controversial, but it is worth considering as it is a safe and cost-effective treatment option.

5. Immunotherapy

Rituximab is a chimeric human/mouse monoclonal antibody against CD20 and B-lymphocyte surface antigens [84]. The function of CD20 is not fully known, and it is thought to be involved in the activation and regulation of B-cells [85]. Although rituximab is a mainstay in the treatment of B-cell NHL, it is not commonly used as monotherapy in OAML patients, and only a few authors have reported the efficacy of this monoclonal antibody [86,87]. Except in the case of relapsed OAML, rituximab shows a good response, but its efficacy is lower than that reported in gastric MALT lymphomas due to its high recurrence rate [87]. Rituximab is also widely used as part of a combination regimen with chemotherapy. For example, the combination of rituximab and chlorambucil showed great success in OAL patients with EMZL and follicular lymphoma as first-line treatment (CR in 89%, PR in 11%, ORR in 100%) [88]. In addition, combination therapy with CHOP (R-CHOP) has improved treatment outcomes in patients with DLBCL and MCL [89,90]. Several authors have reported successful results from intralesional interferon- α injection in conjunctival MALT lymphoma with minimal side effects [91-93], although further research through large clinical trials is needed.

Prognosis

Based on the available scientific literature, the histological subtype may act as the most important predictor of mortality in OAL. One study found that the 5-year lymphoma-related mortality rate was as follows: 12% for EMZL, 19% for diffuse lymphoplasmacytic lymphoma, 22% for follicle center lymphoma, 48% for DLBCL, and 53% for other lymphoma variants (i.e., MCL, chronic lymphocytic lymphoma, etc.) [94]. Another study reported lymphoma-related mortality as 2% for EMZL, 33% for follicular lymphoma, 38% for DLBCL, 100% for MCL, and 100% for peripheral T-cell lymphoma and NK cell lymphoma [95]. Other prognostic factors include the stage at presentation, primary or secondary status, and whether the disease is unilateral or bilateral [95-97]. According to a study, the rates of extraorbital spread and lympho-

ma-related death are the lowest in conjunctival lymphoma, followed by deep orbital lymphoma and lacrimal gland lymphoma, and the highest in eyelid lymphoma [97].

Conclusion

As the most common cancer that occurs in the orbit, the characteristics of OAL should be noted. Furthermore, the incidence of OAL has been reported to increase steadily over the past few decades [5,25,98]. In South Korea, OAML accounts for a particularly higher proportion of OAL compared to that in Western countries [99,100]. The size and location of the tumor should be measured using radiology imaging techniques such as CT and MRI, and an open biopsy should be performed to make a histopathological diagnosis. OAL has different prognostic outcomes depending on its histological subtype, and MALT-type lymphoma has a good ORR if treated properly. Although the TNM staging of OAL is not yet widely used and no large-scale clinical trial has been conducted, further research should be conducted in the future to establish a first-line treatment protocol based on it.

Notes

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Author contributions

Conceptualization, Formal analysis, Project administration, Supervision: JHS; Data curation: HUC; Writing-original draft: HUC; Writing-review & editing: JHS.

ORCID

Hyun Uk Chung, <https://orcid.org/0000-0003-4419-2860>

Jun Hyuk Son, <https://orcid.org/0000-0001-9807-8962>

References

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.
2. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. *Lancet* 2012;380:848–57.
3. Ahmed S, Shahid RK, Sison CP, Fuchs A, Mehrotra B. Orbital lymphomas: a clinicopathologic study of a rare disease. *Am J Med Sci* 2006;331:79–83.
4. Demirci H, Shields CL, Shields JA, Honavar SG, Mercado GJ, Tovilla JC. Orbital tumors in the older adult population. *Ophthalmology* 2002;109:243–8.
5. Margo CE, Mulla ZD. Malignant tumors of the orbit: analysis of the Florida Cancer Registry. *Ophthalmology* 1998;105:185–90.
6. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. *Cancer* 1983;52:1410–6.
7. Rosado MF, Byrne GE Jr, Ding F, Fields KA, Ruiz P, Dubovy SR, et al. Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with *Chlamydia psittaci*. *Blood* 2006;107:467–72.
8. Akpek EK, Polcharoen W, Ferry JA, Foster CS. Conjunctival lymphoma masquerading as chronic conjunctivitis. *Ophthalmology* 1999;106:757–60.
9. Bhatia S, Paulino AC, Buatti JM, Mayr NA, Wen BC. Curative radiotherapy for primary orbital lymphoma. *Int J Radiat Oncol Biol Phys* 2002;54:818–23.
10. Martinet S, Ozsahin M, Belkacemi Y, Landmann C, Poortmans P, Oehler C, et al. Outcome and prognostic factors in orbital lymphoma: a Rare Cancer Network study on 90 consecutive patients treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 2003;55:892–8.
11. Olsen TG, Heegaard S. Orbital lymphoma. *Surv Ophthalmol* 2019;64:45–66.
12. Uno T, Isobe K, Shikama N, Nishikawa A, Oguchi M, Ueno N, et al. Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. *Cancer* 2003;98:865–71.
13. Sjö LD. Ophthalmic lymphoma: epidemiology and pathogenesis. *Acta Ophthalmol* 2009;87(Thesis 1):1–20.
14. van der Gaag R. Immunological responses in the eyelid and orbit. *Eye (Lond)* 1988;2(Pt 2):158–63.
15. Du MQ, Isaacson PG. Gastric MALT lymphoma: from aetiology to treatment. *Lancet Oncol* 2002;3:97–104.
16. Ferreri AJ, Guidoboni M, Ponzoni M, De Conciliis C, Dell’Oro S, Fleischhauer K, et al. Evidence for an association between *Chlamydia psittaci* and ocular adnexal lymphomas. *J Natl Cancer Inst* 2004;96:586–94.
17. Byrne GI, Ojcius DM. Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. *Nat Rev Microbiol* 2004;2:802–8.
18. Collina F, De Chiara A, De Renzo A, De Rosa G, Botti G, Franco R. *Chlamydia psittaci* in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution. *Infect Agent Cancer* 2012;7:8.

19. Chanudet E, Zhou Y, Bacon CM, Wotherspoon AC, Müller-Hermelink HK, Adam P, et al. Chlamydia psittaci is variably associated with ocular adnexal MALT lymphoma in different geographical regions. *J Pathol* 2006;209:344–51.
20. Coupland SE. Molecular pathology of lymphoma. *Eye (Lond)* 2013;27:180–9.
21. Daibata M, Nemoto Y, Togitani K, Fukushima A, Ueno H, Ouchi K, et al. Absence of Chlamydia psittaci in ocular adnexal lymphoma from Japanese patients. *Br J Haematol* 2006;132:651–2.
22. Mulder MM, Heddema ER, Pannekoek Y, Faridpooya K, Oud ME, Schilder-Tol E, et al. No evidence for an association of ocular adnexal lymphoma with Chlamydia psittaci in a cohort of patients from the Netherlands. *Leuk Res* 2006;30:1305–7.
23. Vargas RL, Fallone E, Felgar RE, Friedberg JW, Arbini AA, Andersen AA, et al. Is there an association between ocular adnexal lymphoma and infection with Chlamydia psittaci?: the University of Rochester experience. *Leuk Res* 2006;30:547–51.
24. Bayraktar S, Bayraktar UD, Stefanovic A, Lossos IS. Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients. *Br J Haematol* 2011;152:72–80.
25. Bernardini FP, Bazzan M. Lymphoproliferative disease of the orbit. *Curr Opin Ophthalmol* 2007;18:398–401.
26. Ferreri AJ, Govi S, Pasini E, Mappa S, Bertoni F, Zaja F, et al. Chlamydia psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexal lymphoma: final results of an international phase II trial. *J Clin Oncol* 2012;30:2988–94.
27. Ferreri AJ, Ponzoni M, Guidoboni M, Resti AG, Politi LS, Cortelazzo S, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. *J Natl Cancer Inst* 2006;98:1375–82.
28. Ferreri AJ, Viale E, Guidoboni M, Resti AG, De Conciliis C, Politi L, et al. Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. *Ann Oncol* 2006;17:769–72.
29. Fischbach W. Gastric MALT lymphoma: update on diagnosis and treatment. *Best Pract Res Clin Gastroenterol* 2014;28:1069–77.
30. Achenbach CJ, Cole SR, Kitahata MM, Casper C, Willig JH, Mugavero MJ, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. *AIDS* 2011;25:691–700.
31. Riedel DJ, Rositch AF, Redfield RR, Blattner WA. HIV-associated lymphoma sub-type distribution, immunophenotypes and survival in an urban clinic population. *Leuk Lymphoma* 2016;57:306–12.
32. Bruyand M, Thiébaud R, Lawson-Ayayi S, Joly P, Sascó AJ, Mercié P, et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. *Clin Infect Dis* 2009;49:1109–16.
33. Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FH-DH-ANRS CO4): a prospective cohort study. *Lancet Oncol* 2009;10:1152–9.
34. Zoufaly A, Stellbrink HJ, Heiden MA, Kollan C, Hoffmann C, van Lunzen J, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. *J Infect Dis* 2009;200:79–87.
35. Teixeira Mendes LS, Wotherspoon A. Marginal zone lymphoma: associated autoimmunity and auto-immune disorders. *Best Pract Res Clin Haematol* 2017;30:65–76.
36. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. *Arch Intern Med* 2005;165:2337–44.
37. Du MQ. MALT lymphoma: many roads lead to nuclear factor- κ B activation. *Histopathology* 2011;58:26–38.
38. Ruiz A, Reischl U, Swerdlow SH, Hartke M, Streubel B, Procop G, et al. Extranodal marginal zone B-cell lymphomas of the ocular adnexa: multiparameter analysis of 34 cases including interphase molecular cytogenetics and PCR for Chlamydia psittaci. *Am J Surg Pathol* 2007;31:792–802.
39. Tanimoto K, Sekiguchi N, Yokota Y, Kaneko A, Watanabe T, Maeshima AM, et al. Fluorescence in situ hybridization (FISH) analysis of primary ocular adnexal MALT lymphoma. *BMC Cancer* 2006;6:249.
40. Priego G, Majos C, Climent F, Muntane A. Orbital lymphoma: imaging features and differential diagnosis. *Insights Imaging* 2012;3:337–44.
41. Eissa L, Abdel Razek AA, Helmy E. Arterial spin labeling and diffusion-weighted MR imaging: utility in differentiating idiopathic orbital inflammatory pseudotumor from orbital lymphoma. *Clin Imaging* 2021;71:63–8.
42. Politi LS, Forghani R, Godi C, Resti AG, Ponzoni M, Bianchi S, et al. Ocular adnexal lymphoma: diffusion-weighted MR imaging for differential diagnosis and therapeutic monitoring. *Radiology* 2010;256:565–74.
43. Isaacson PG, Norton AJ. Extranodal lymphomas. Edinburgh: Churchill Livingstone; 1996.
44. Mannami T, Yoshino T, Oshima K, Takase S, Kondo E, Ohara

- N, et al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. *Mod Pathol* 2001;14:641–9.
45. Kremer M, Cabras AD, Fend F, Schulz S, Schwarz K, Hoefler H, et al. PCR analysis of IgH-gene rearrangements in small lymphoid infiltrates microdissected from sections of paraffin-embedded bone marrow biopsy specimens. *Hum Pathol* 2000;31:847–53.
 46. Adachi A, Tamaru J, Kaneko K, Kuroda H, Miura I, Kojima T, et al. No evidence of a correlation between BCL10 expression and API2-MALT1 gene rearrangement in ocular adnexal MALT lymphoma. *Pathol Int* 2004;54:16–25.
 47. Coupland SE, Damato B. Lymphomas involving the eye and the ocular adnexa. *Curr Opin Ophthalmol* 2006;17:523–31.
 48. Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. *Graefes Arch Clin Exp Ophthalmol* 2004;42:130–45.
 49. Coupland SE, Krause L, Delecluse HJ, Anagnostopoulos I, Foss HD, Hummel M, et al. Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases. *Ophthalmology* 1998;105:1430–41.
 50. Ferreri AJ, Dolcetti R, Du MQ, Doglioni C, Resti AG, Politi LS, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. *Ann Oncol* 2008;19:835–46.
 51. Franco R, Camacho FI, Caleo A, Staibano S, Bifano D, De Renzo A, et al. Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. *Mod Pathol* 2006;19:1055–67.
 52. Bouali S, Said IB, Yedeas MD, Abderrahmen K, Maatar N, Bou-baker A, et al. Primary sporadic Burkitt lymphoma of the orbit, clinical characteristics, management, and outcomes: a case study. *Childs Nerv Syst* 2016;32:437–40.
 53. Rasmussen P, Sjö LD, Prause JU, Ralfkiaer E, Heegaard S. Mantle cell lymphoma in the orbital and adnexal region. *Br J Ophthalmol* 2009;93:1047–51.
 54. Armitage JO. Staging non-Hodgkin lymphoma. *CA Cancer J Clin* 2005;55:368–76.
 55. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. *Cancer Res* 1971;31:1860–1.
 56. Coupland SE, White VA, Rootman J, Damato B, Finger PT. A TNM-based clinical staging system of ocular adnexal lymphomas. *Arch Pathol Lab Med* 2009;133:1262–7.
 57. Rosenberg SA, Boiron M, DeVita VT Jr, Johnson RE, Lee BJ, Ultmann JE, Viamonte M Jr. Report of the Committee on Hodgkin's Disease Staging Procedures. *Cancer Res* 1971;31:1862–3.
 58. Graue GF, Finger PT, Maher E, Della Rocca D, Della Rocca R, Lelli GJ Jr, et al. Ocular adnexal lymphoma staging and treatment: American Joint Committee on Cancer versus Ann Arbor. *Eur J Ophthalmol* 2013;23:344–55.
 59. Lee SE, Paik JS, Cho WK, Choi BO, Lee SN, Jung SE, et al. Feasibility of the TNM-based staging system of ocular adnexal extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). *Am J Hematol* 2011;86:262–6.
 60. Amin MB, Edge SB, Greene F, Byrd DR, Brookland RK, Washington MK, et al. *AJCC cancer staging manual*. 8th ed. New York: Springer; 2017.
 61. Tanimoto K, Kaneko A, Suzuki S, Sekiguchi N, Maruyama D, Kim SW, et al. Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. *Ann Oncol* 2006;17:135–40.
 62. Cohen VM. Treatment options for ocular adnexal lymphoma (OAL). *Clin Ophthalmol* 2009;3:689–92.
 63. Fung CY, Tarbell NJ, Lucarelli MJ, Goldberg SI, Linggood RM, Harris NL, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. *Int J Radiat Oncol Biol Phys* 2003;57:1382–91.
 64. Bolek TW, Moyses HM, Marcus RB Jr, Gorden L 3rd, Maiese RL, Almasri NM, et al. Radiotherapy in the management of orbital lymphoma. *Int J Radiat Oncol Biol Phys* 1999;44:31–6.
 65. Goda JS, Le LW, Lapperriere NJ, Millar BA, Payne D, Gospodarowicz MK, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. *Int J Radiat Oncol Biol Phys* 2011;81:e659–66.
 66. Stafford SL, Kozelsky TF, Garrity JA, Kurtin PJ, Leavitt JA, Martenson JA, et al. Orbital lymphoma: radiotherapy outcome and complications. *Radiation Oncol* 2001;59:139–44.
 67. Yen MT, Bilyk JR, Wladis EJ, Bradley EA, Mawn LA. Treatments for ocular adnexal lymphoma: a report by the American Academy of Ophthalmology. *Ophthalmology* 2018;125:127–36.
 68. Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. *Int J Radiat Oncol Biol Phys* 2013;86:930–5.
 69. Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nas-toupil L, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. *Head Neck* 2017;39:1095–100.

70. Ben Simon GJ, Cheung N, McKelvie P, Fox R, McNab AA. Oral chlorambucil for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue of the orbit. *Ophthalmology* 2006;113:1209–13.
71. Jäger G, Neumeister P, Quehenberger F, Wöhrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. *Ann Oncol* 2006;17:1722–3.
72. Raderer M, Wöhrer S, Bartsch R, Prager G, Drach J, Hejna M, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. *J Clin Oncol* 2005;23:8442–6.
73. Zinzani PL, Stefoni V, Musuraca G, Tani M, Alinari L, Gabriele A, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. *Cancer* 2004;100:2190–4.
74. Kim JS, Kang SH, Moon HS, Sung JK, Jeong HY. Clinical outcome of eradication therapy for gastric mucosa-associated lymphoid tissue lymphoma according to *H. pylori* infection status. *Gastroenterol Res Pract* 2016;2016:6794848.
75. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. *Nat Rev Cancer* 2004;4:644–53.
76. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. *Helicobacter pylori*-associated gastritis and primary B-cell gastric lymphoma. *Lancet* 1991;338:1175–6.
77. Yoo C, Ryu MH, Huh J, Park JH, Kang HJ, Ahn HS, et al. *Chlamydia psittaci* infection and clinicopathologic analysis of ocular adnexal lymphomas in Korea. *Am J Hematol* 2007;82:821–3.
78. Liu YC, Ohyashiki JH, Ito Y, Iwaya K, Serizawa H, Mukai K, et al. *Chlamydia psittaci* in ocular adnexal lymphoma: Japanese experience. *Leuk Res* 2006;30:1587–9.
79. de Cremoux P, Subtil A, Ferreri AJ, Vincent-Salomon A, Ponzoni M, Chaoui D, et al. Re: Evidence for an association between *Chlamydia psittaci* and ocular adnexal lymphomas. *J Natl Cancer Inst* 2006;98:365–6.
80. Gracia E, Froesch P, Mazzucchelli L, Martin V, Rodríguez-Abreu D, Jiménez J, et al. Low prevalence of *Chlamydia psittaci* in ocular adnexal lymphomas from Cuban patients. *Leuk Lymphoma* 2007;48:104–8.
81. Zhang GS, Winter JN, Variakojis D, Reich S, Lissner GS, Bryar P, et al. Lack of an association between *Chlamydia psittaci* and ocular adnexal lymphoma. *Leuk Lymphoma* 2007;48:577–83.
82. Han JJ, Kim TM, Jeon YK, Kim MK, Khwarg SI, Kim CW, et al. Long-term outcomes of first-line treatment with doxycycline in patients with previously untreated ocular adnexal marginal zone B cell lymphoma. *Ann Hematol* 2015;94:575–81.
83. Grünberger B, Hauff W, Lukas J, Wöhrer S, Zielinski CC, Streubel B, et al. 'Blind' antibiotic treatment targeting *Chlamydia* is not effective in patients with MALT lymphoma of the ocular adnexa. *Ann Oncol* 2006;17:484–7.
84. Tuncer S, Tanyıldız B, Basaran M, Buyukbabani N, Dogan O. Systemic rituximab immunotherapy in the management of primary ocular adnexal lymphoma: single institution experience. *Curr Eye Res* 2015;40:780–5.
85. Riley JK, Sliwkowski MX. CD20: a gene in search of a function. *Semin Oncol* 2000;27(6 Suppl 12):17–24.
86. Annibaldi O, Chiodi F, Sarlo C, Cortes M, Quaranta-Leoni FM, Quattrocchi C, et al. Rituximab as single agent in primary MALT lymphoma of the ocular adnexa. *Biomed Res Int* 2015;2015:895105.
87. Ferreri AJ, Ponzoni M, Martinelli G, Muti G, Guidoboni M, Dolcetti R, et al. Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa. *Haematologica* 2005;90:1578–9.
88. Rigacci L, Nassi L, Puccioni M, Mappa S, Polito E, Dal Pozzo S, et al. Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas. *Ann Hematol* 2007;86:565–8.
89. Knudsen MK, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF, et al. Clinicopathological features of ocular adnexal mantle-cell lymphoma in an international multicenter cohort. *JAMA Ophthalmol* 2017;135:1367–74.
90. Rasmussen PK. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features. *Acta Ophthalmol* 2013;91(Thesis 5):1–27.
91. Blasi MA, Gherlinzoni F, Calvisi G, Sasso P, Tani M, Cellini M, et al. Local chemotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report. *Ophthalmology* 2001;108:559–62.
92. Blasi MA, Tiberti AC, Valente P, Laguardia M, Sammarco MG, Balestrazzi A, et al. Intralesional interferon- α for conjunctival mucosa-associated lymphoid tissue lymphoma: long-term results. *Ophthalmology* 2012;119:494–500.
93. Lachapelle KR, Rathee R, Kratky V, Dexter DF. Treatment of conjunctival mucosa-associated lymphoid tissue lymphoma with intralesional injection of interferon alfa-2b. *Arch Ophthalmol* 2000;118:284–5.
94. Jenkins C, Rose GE, Bunce C, Wright JE, Cree IA, Plowman N, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. *Br J Ophthalmol* 2000;84:907–13.
95. McKelvie PA, McNab A, Francis IC, Fox R, O'Day J. Ocular ad-

- nexal lymphoproliferative disease: a series of 73 cases. *Clin Exp Ophthalmol* 2001;29:387-93.
96. Sullivan TJ, Whitehead K, Williamson R, Grimes D, Schlect D, Brown I, et al. Lymphoproliferative disease of the ocular adnexa: a clinical and pathologic study with statistical analysis of 69 patients. *Ophthalmic Plast Reconstr Surg* 2005;21:177-88.
 97. Jenkins C, Rose GE, Bunce C, Cree I, Norton A, Plowman PN, et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. *Eye (Lond)* 2003;17:809-20.
 98. Moslehi R, Devesa SS, Schairer C, Fraumeni JF Jr. Rapidly increasing incidence of ocular non-hodgkin lymphoma. *J Natl Cancer Inst* 2006;98:936-9.
 99. Cho EY, Han JJ, Ree HJ, Ko YH, Kang YK, Ahn HS, et al. Clinicopathologic analysis of ocular adnexal lymphomas: extranodal marginal zone b-cell lymphoma constitutes the vast majority of ocular lymphomas among Koreans and affects younger patients. *Am J Hematol* 2003;73:87-96.
 100. Lee JL, Kim MK, Lee KH, Hyun MS, Chung HS, Kim DS, et al. Extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue-type of the orbit and ocular adnexa. *Ann Hematol* 2005;84:13-8.